Peanut Allergy clinical trials at UCSF
2 in progress, 0 open to eligible people
Showing trials for
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Sorry, in progress, not accepting new patients
Open-label, follow-up study for subjects who completed the EPITOPE study.
San Francisco, California and other locations
Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Sorry, in progress, not accepting new patients
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
San Francisco, California and other locations
Our lead scientists for Peanut Allergy research studies include Morna Dorsey.